Gilead set to sew up Sovaldi licensing for 75 developing nations
This article was originally published in Scrip
Executive Summary
Gilead Sciences appears close to finalizing Mylan as one of its partners for its hepatitis C treatment, Sovaldi (sofosbuvir), in India and a clutch of developing nations.